RFAI · RF Acquisition Corp II · Stock research

Public research note. Nothing here is investment advice or a recommendation to buy or sell any security.

RFAI — RF Acquisition Corp II

Current Thesis

RFAI is a Cayman blank-check company that has been emptied of almost all its public shares and is now trading as a supply accident. At the 2026-08-19 extraordinary general meeting the business combination with NYB Holdings / Nanyang Biologics Pte. Ltd. Passed 6,765,584 for against 440,604. 98.95% of the shares outstanding after the 12 August redemption. The share count that remains freely tradable is therefore about one percent of an already small public base, and the market repriced it accordingly: RFAI closed 2026-08-21 at $58.00, up 355.6% on the day and 524.3% on the week, with an intraday range of $35.22 to $73.00 and an after-hours print of $48.00.

The narrative leg being bought is mechanical, not clinical. It is float scarcity against a $1.5B headline pre-transaction valuation and an AI-drug-discovery story, in a name where the deal is approved and the closing is pending.

Bullish and bearish views on RF Acquisition Corp II

The model's bull view on RF Acquisition Corp II (RFAI), in brief: Redemptions removed the supply. 3,956,323 of 3,998,108 public shares requested redemption into the 2026-08-19 vote (98.95%), per the results filed 2026-08-20. Any residual demand meets a share count that a single retail scan can move. The deal cleared its votes. All merger… The bear view: The company lists with essentially no cash from the SPAC. Both cases follow in full.

Bull Case

• Redemptions removed the supply. 3,956,323 of 3,998,108 public shares requested redemption into the 2026-08-19 vote (98.95%), per the results filed 2026-08-20. Any residual demand meets a share count that a single retail scan can move.
• The deal cleared its votes. All merger, governance, Nasdaq and incentive-plan proposals passed on 2026-08-19; the Form F-4 registration statement for NYB Holdings was declared effective by the SEC ahead of the meeting. The path to a Nasdaq listing under the reserved ticker "NYB" is procedurally open, subject to customary closing conditions.
• A named, listed sponsor-adjacent holder. The9 Limited (NCTY), via Gamenow.net (Hong Kong) Limited, is an existing NYB shareholder and is expected to hold 15%–16% of the combined company after closing (The9 press release, 2026-08-21). That gives the story a second listed vehicle and a promotional channel.
• Story fuel with a number attached. The transaction assigns NYB a pre-transaction valuation of approximately US$1.5 billion. NYB's Vecura AI platform screens a proprietary library of more than one million natural compounds for drug candidates — the "AI × drug discovery" framing that small-cap momentum flows have paid up for repeatedly since 2023.
• Attention arrived on 2026-08-21, not before. RFAI appeared in Benzinga's premarket movers list that morning alongside HOWL, SUGP, SDEV, ZKH, BTAI, SXTC, TREO and ASST — a first, not a fifth, day of coverage.

Bear Case

• The company lists with essentially no cash from the SPAC. If the 3,956,323 preliminary redemption requests stand at ~$11.13 per share, the trust is very nearly consumed; ts2.tech's 2026-08-21 arithmetic on the disclosed figures puts residual trust near $0.49 million. RFAI reported cash outside trust of $10,191 and a working capital deficit of $1.28 million at 2026-06-30. No PIPE or backstop financing was quantified in the filings and coverage reviewed for this note.
• $11.13 is the only anchored value in the structure. That is what the trust paid redeeming holders on 2026-08-12. The 2026-08-21 close of $58.00 sits at a multiple of it, supported by scarcity rather than by any disclosed NYB revenue — no NYB revenue figure appeared in the sources reviewed.
• The float that squeezes is the float that disappears. On closing, RFAI ordinary shares convert into NYB Holdings shares and the ticker changes. The combined-company share count then includes founder shares and the target's rollover equity against a ~$1.5B valuation. A post-close resale registration statement, when filed, is the mechanism that converts locked stock into supply.
• Nasdaq's initial-listing tests for the post-combination entity include public-holder and public-float minimums. Whether 98.95% redemptions leave those satisfied is not established in what has been filed publicly. An observable would be a deficiency notice or a delayed listing after closing.
• Friday already gave back a third of the high. $73.00 high, $58.00 close, $48.00 after-hours. The distribution began inside the first full session of the move.

Setup & Price Structure

Price: the 2026-08-21 close of $58.00 is the 52-week high, 0.0% from it, with a three-month price change of +427.8% and RSI(14) at 96.3. There is no moving-average structure worth naming — the entire move is two sessions old and the 2026-08-21 range alone spanned $35.22 to $73.00.

Crowding and positioning observables, stated as observables:

• RSI(14) 96.3 and price at the 52-week high on the same close.
• Intraday reversal on the breakout session: high $73.00, close $58.00, after-hours $48.00 (−17.2% from the close).
• Coverage clustering the same morning — three separate 2026-08-21 Benzinga items on RFAI, including a generic premarket-movers list, which is scan-driven retail attention rather than institutional initiation. No sell-side price target on RFAI was found; the name has no analyst coverage.
• No earnings date is pending; a SPAC shell has no operating print to miss.
• The insider/issuance angle here is structural rather than a Form 4: the near-100% redemption plus the pending conversion means the share count is scheduled to expand, not from a secondary but from the merger mechanics themselves.

Life-cycle label: ACCELERATING, dated to 2026-08-20 (EGM results filed) and 2026-08-21 (the +355.6% session and first broad coverage). The qualifier that matters: in redemption-squeeze names the accelerating and saturated phases can be days apart, and the mechanic has a scheduled end. The condition that would date a flip to SATURATED is closing plus the ticker conversion to NYB with the first post-close resale registration on file, or two consecutive lower daily highs on declining volume from here.

Catalyst Calendar (next 30 days)

• ~2026-08-24 to ~2026-09-15 (est.) — closing of the business combination. No closing date has been publicly announced. The deal remains subject to customary closing conditions after the 2026-08-19 approval. This is the single event that resolves the float question.
• ~within 4 business days of closing (est., so ~2026-09-04 if closing lands early September) — the closing report. Final redemption count, final trust cash and the post-close share count get disclosed here for the first time. Everything about the current setup is preliminary until this document exists.
• ~closing date (est.) — Nasdaq listing and ticker conversion to "NYB." RFAI ceases to trade; holders track the successor symbol. Any listing deficiency or delay surfaces in this window.
• ~2026-09 to ~2026-11 (est.) — post-close resale registration statement. The filing that begins converting restricted holdings into tradable supply. Timing is issuer-discretionary and unannounced.
• 2027-02-15 — outside deadline to complete a business combination, per the extension approved 2026-08-12, achievable in up to six one-month steps at $75,000 deposited into trust per extension. Relevant only in the scenario where closing does not occur.

What Would Change Our Mind

The structure that breaks first is the 2026-08-21 session itself. That day's low of $35.22 is the only floor the move has built; below it, there is no intervening structure between the market price and the $11.13 trust redemption value that redeeming holders were paid on 2026-08-12. A daily close below $35 forfeits the entire squeeze-session range and ends the scarcity leg.

Three non-price conditions would independently change the read:

1. a backstop, a non-redemption agreement, withdrawn requests — the scarcity premise is simply not there, and the name reprices toward whatever the combined company is worth on its disclosures.
2. The resale registration statement is filed. Restricted stock becoming saleable against a public share count this small is the supply event the current price does not reflect.
3. The closing date passes without a closing. Approval is not consummation. Each month of extension costs $75,000 into trust and pushes the terminal date toward 2027-02-15; a stalled closing removes the reason the move started while leaving the price where the squeeze left it.

Conversely, evidence that would extend rather than break the read: a closing report confirming redemptions at or near the preliminary 98.95%, a Nasdaq listing that proceeds on schedule, and no resale registration on file.

Correlation Notes

• The9 Limited (NCTY) is the readable proxy — expected 15%–16% owner of the combined company post-close (2026-08-21 press release). NCTY's reaction to the same headline is the cleanest external check on whether the market is pricing NYB's business or RFAI's float.
• The correlation that dominates is not sectoral. RFAI's 2026-08-21 co-movers in the premarket lists (HOWL up on a $33 million EMD Serono deal, SUGP, SDEV, ZKH, BTAI, SXTC, TREO, ASST) share a screen, not an end market. This name trades with the small-cap momentum-scan bid and with de-SPAC redemption squeezes generally, which have historically retraced most of the vertical move once the float mechanic resolves — an observation about the cohort, not a forecast for this ticker.
• Macro was a tailwind, not the driver. On 2026-08-21 the Dow gained 350–400 points and the S&P Composite PMI printed its strongest reading since April 2022. A +355.6% session is idiosyncratic; the beta contribution is negligible.
• The eventual comparison set — listed AI-drug-discovery platforms — becomes relevant only after closing, when NYB's own disclosures replace the $1.5B pre-transaction headline. Until the closing report is filed, there is no operating comparison to run.